Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Ira M. Jacobson,Ira M. Jacobson,Eric Lawitz,Edward Gane,Bernard Willems,Peter Ruane,Ronald Nahass,Sergio Borgia,Stephen D. Shafran,Kimberly A. Workowski,Brian L. Pearlman,Robert H. Hyland,Luisa M. Stamm,Evguenia S. Svarovskaia,Hadas Dvory-Sobol,Yanni Zhu,G. Mani Subramanian,Diana M. Brainard,John G. McHutchison,Norbert Bräu,Norbert Bräu,Thomas Berg,Kosh Agarwal,Bal Raj Bhandari,M. Davis,Jordan J. Feld,Gregory J. Dore,Catherine A.M. Stedman,Alexander J. Thompson,Tarik Asselah,Stuart K. Roberts,Graham R. Foster +31 more
Reads0
Chats0
TLDR
In phase 3 trials of patients with HCV infection, it was not established that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofOSbuvir -velpat asvir for 12 weeks, but the 2 regimens had similar rates of SVR in patients withHCV genotype 3 and cirrhosis.About:
This article is published in Gastroenterology.The article was published on 2017-07-01 and is currently open access. It has received 193 citations till now. The article focuses on the topics: Glecaprevir & Voxilaprevir.read more
Citations
More filters
Journal ArticleDOI
[Antiviral therapy of chronic hepatitis C: 30 years success story].
D.T. Abdurakhmanov,Абдурахманов Джамал Тинович,T. P. Rozina,Розина Тэона Павловна,E N Nikulkina,Никулкина Елена Николаевна,E Z Burnevich,Бурневич Эдуард Збигневич,E.L. Tanashuk,Танащук Елена Львовна,M.V. Severov,Северов Михаил Викторович,A L Filatova,Филатова Анна Львовна,S Yu Milovanova,Милованова Светлана Юрьевна,V.V. Karpov,Карпов Владимир Владимирович,S.V. Moiseev,Моисеев Сергей Валентинович +19 more
TL;DR: The greatest progress in treatment was noted over the past 5 years when drugs with direct antiviral action appeared and began to be widely used, including in Russia, which ensure the elimination of the virus in 90-95% of cases.
Journal ArticleDOI
Direct-acting antiviral regimens and HCV treatment failure and re-treatment in sub-Saharan Africa.
TL;DR: The findings do not support the use of sofosbuvir–ledipasvir as the initial therapy for HCV infection without genotype subtyping in this region and the suitability of alternative direct-acting antiviral regimens in treatment-naive patients and in patients with a history of direct- acting antiviral treatment failure is investigated.
Book ChapterDOI
Management of Hepatitis C Viral Infection in People Who Inject Drugs
G. Robaeys,Rob Bielen +1 more
TL;DR: In this paper, the authors discuss HCV infection in persons who inject drugs (PWID) or who have ever injected drugs are the largest group at risk, with special attention on the barriers to care and how to overcome them.
Journal ArticleDOI
Direct-acting antiviral regimens and HCV treatment failure and re-treatment in sub-Saharan Africa
TL;DR: In this paper , a 12-week course of direct-acting antiviral treatment for chronic hepatitis C virus (HCV) infection was shown to be effective when administered as combination therapies.
Journal ArticleDOI
Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China
Yilihamu Abulitifu,Jiangshan Lian,Munire Adilijiang,Lan-xia Liu,Fengcong Zhao,Wenxi Qian,Yongping Zhang +6 more
TL;DR: In this paper , the effectiveness and safety of SOF/VEL with and without ribavirin (RBV) in patients with GT3-infection-related cirrhosis from Xinjiang, China was investigated.
References
More filters
Journal ArticleDOI
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Jordan J. Feld,Ira M. Jacobson,Christophe Hézode,Tarik Asselah,Peter Ruane,Norbert Gruener,Armand Abergel,Alessandra Mangia,Ching-Lung Lai,Henry Lik Yuen Chan,Francesco Mazzotta,Christophe Moreno,Eric M. Yoshida,Stephen D. Shafran,William J. Towner,Tram T. Tran,John McNally,Anu Osinusi,Evguenia S. Svarovskaia,Yanni Zhu,Diana M. Brainard,John G. McHutchison,Kosh Agarwal,Stefan Zeuzem +23 more
TL;DR: Once-daily sofosbuvir-velpatasvir for 12 weeks provided high rates of sustained virologic response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis.
Journal ArticleDOI
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz,Mark S. Sulkowski,Reem Ghalib,Maribel Rodriguez-Torres,Zobair M. Younossi,Ana Corregidor,Edwin DeJesus,Brian L. Pearlman,Mordechai Rabinovitz,Norman Gitlin,Joseph K. Lim,Paul J. Pockros,John D. Scott,Bart Fevery,Tom Lambrecht,Sivi Ouwerkerk-Mahadevan,Katleen Callewaert,William T. Symonds,Gaston Picchio,Karen L Lindsay,Maria Beumont,Ira M. Jacobson +21 more
TL;DR: Combined simeprevir and sofosbuvir was efficacious and well tolerated in chronic HCV genotype 1 infections and sustained virological response 12 weeks after stopping treatment was achieved.
Journal ArticleDOI
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R. Foster,Nezam H. Afdhal,Stuart K. Roberts,Norbert Bräu,E.J. Gane,S. Pianko,E.J. Lawitz,Alexander J. Thompson,Mitchell L. Shiffman,Curtis L Cooper,William J. Towner,Brian Conway,Peter Ruane,M. Bourliere,Tarik Asselah,Thomas Berg,S. Zeuzem,William Rosenberg,Kosh Agarwal,Catherine A.M. Stedman,Hongmei Mo,Hadas Dvory-Sobol,Lingling Han,Jing Wang,John McNally,Anu Osinusi,Diana M. Brainard,John G. McHutchison,Francesco Mazzotta,Tram T. Tran,Stuart C. Gordon,Keyur Patel,Nancy Reau,Alessandra Mangia,Mark S. Sulkowski +34 more
TL;DR: Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.
Journal ArticleDOI
Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection
Marc Bourlière,Stuart C. Gordon,Steven L. Flamm,Curtis Cooper,Alnoor Ramji,Myron J. Tong,Natarajan Ravendhran,John M. Vierling,Tram T. Tran,S. Pianko,Meena B. Bansal,Victor de Ledinghen,Robert H. Hyland,Luisa M. Stamm,Hadas Dvory-Sobol,Evguenia S. Svarovskaia,Jie Zhang,K.C. Huang,G. Mani Subramanian,Diana M. Brainard,John G. McHutchison,Elizabeth C. Verna,Peter Buggisch,Charles S. Landis,Ziad Younes,Michael P. Curry,Simone I. Strasser,Eugene R. Schiff,K. Rajender Reddy,Michael P. Manns,Kris V. Kowdley,Stefan Zeuzem +31 more
TL;DR: Sofosbuvir‐velpatasvir‐voxilaprevir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV genotypes in whom treatment with a DAA regimen had previously failed.
Journal ArticleDOI
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
TL;DR: Results obtained with oral DAA combinations that have been approved and/or have completed phase 3 clinical trials for HCV infection are summarized and future perspectives are discussed.
Related Papers (5)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R. Foster,Nezam H. Afdhal,Stuart K. Roberts,Norbert Bräu,E.J. Gane,S. Pianko,E.J. Lawitz,Alexander J. Thompson,Mitchell L. Shiffman,Curtis L Cooper,William J. Towner,Brian Conway,Peter Ruane,M. Bourliere,Tarik Asselah,Thomas Berg,S. Zeuzem,William Rosenberg,Kosh Agarwal,Catherine A.M. Stedman,Hongmei Mo,Hadas Dvory-Sobol,Lingling Han,Jing Wang,John McNally,Anu Osinusi,Diana M. Brainard,John G. McHutchison,Francesco Mazzotta,Tram T. Tran,Stuart C. Gordon,Keyur Patel,Nancy Reau,Alessandra Mangia,Mark S. Sulkowski +34 more
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Jordan J. Feld,Ira M. Jacobson,Christophe Hézode,Tarik Asselah,Peter Ruane,Norbert Gruener,Armand Abergel,Alessandra Mangia,Ching-Lung Lai,Henry Lik Yuen Chan,Francesco Mazzotta,Christophe Moreno,Eric M. Yoshida,Stephen D. Shafran,William J. Towner,Tram T. Tran,John McNally,Anu Osinusi,Evguenia S. Svarovskaia,Yanni Zhu,Diana M. Brainard,John G. McHutchison,Kosh Agarwal,Stefan Zeuzem +23 more
Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis
Michael P. Curry,Jacqueline G. O'Leary,Natalie Bzowej,Andrew J. Muir,Kevin M. Korenblat,Jonathan M. Fenkel,K. R. Reddy,E. Lawitz,Steven L. Flamm,T. Schiano,L. Teperman,Robert J. Fontana,E. Schiff,Michael W. Fried,Brian P. Doehle,D. An,J. McNally,A. O. Osinusi,Diana M. Brainard,John G. McHutchison,Robert S. Brown,Michael Charlton +21 more
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach,Stefan Zeuzem,Michael Manns,Ibrahim Altraif,Ann-Sofi Duberg,David H. Muljono,Imam Waked,Seyed M Alavian,Mei Hsuan Lee,Francesco Negro,Faisal Abaalkhail,Ahmed Abdou,Maheeba Abdulla,Antoine Abou Rached,Inka Aho,Ulus Salih Akarca,Imad Al Ghazzawi,Saad Al Kaabi,Faryal Al Lawati,Khalid Al Namaani,Youssif Al Serkal,Said A. Al-Busafi,Layla Al-Dabal,Soo Aleman,Abdullah S. Alghamdi,Abdulrahman Aljumah,Hamad Al-Romaihi,Monique Andersson,Vic Arendt,Perttu Arkkila,Abdullah M. Assiri,Oidov Baatarkhuu,Abate Bane,Ziv Ben-Ari,Colm Bergin,Fernando Bessone,Florian Bihl,Abdul Rahman Bizri,M. Blachier,Antonio Javier Blasco,Carlos E Brandão Mello,Philip Bruggmann,Cheryl Brunton,Filipe Calinas,Henry Lik-Yuen Chan,Asad Chaudhry,Hugo Cheinquer,Chien-Jen Chen,Rong-Nan Chien,Moon Seok Choi,Peer Brehm Christensen,Wan-Long Chuang,Vladimir Chulanov,Laura Cisneros,Mette Rye Clausen,Matthew E. Cramp,Antonio Craxì,E. A. Croes,Olav Dalgard,Jorge Daruich,Victor de Ledinghen,Gregory J. Dore,Manal H El-Sayed,Gül Ergör,Gamal Esmat,Chris Estes,Karolin Falconer,Elmoubashar Farag,Maria Lucia Gomes Ferraz,Paulo R. Ferreira,Robert Flisiak,Sona Frankova,Ivane Gamkrelidze,Edward Gane,Javier García-Samaniego,Akram Khan,Ilias Gountas,Adrian Goldis,Magnus Gottfredsson,Jason Grebely,Michael Gschwantler,Mario G. Pessoa,Jessie Gunter,Behzad Hajarizadeh,Omer Hajelssedig,Saeed Hamid,Waseem Hamoudi,Angelos Hatzakis,Sayed Himatt,Harald Hofer,Irena Hrstić,Yee Tak Hui,Béla Hunyady,Ramazan Idilman,Wasim Jafri,Rohani Jahis,Naveed Z. Janjua,Peter Jarcuska,Agita Jeruma,Jon G. Jonasson,Yasser Kamel,Jia-Horng Kao,Sabahattin Kaymakoglu,David Kershenobich,Jawad Khamis,Young Sik Kim,Loreta A. Kondili,Zaher Koutoubi,Mel Krajden,Henrik Krarup,Moon sing Lai,Wim Laleman,Wai-cheung C Lao,Daniel Lavanchy,Pablo Lázaro,Henri Leleu,Olufunmilayo A. Lesi,Laurentius A. Lesmana,Michael Li,Valentina Liakina,Young-Suk Lim,Boris Lukšić,Adam Mahomed,Matti Maimets,Mihály Makara,Abraham O. Malu,Rui Tato Marinho,Paul Marotta,Stefan Mauss,Muhammad S. Memon,Maria C Mendes Correa,Nahum Méndez-Sánchez,Shahin Merat,Ammal M. Metwally,Rosmawati Mohamed,Christophe Moreno,Fadi H. Mourad,Beat Müllhaupt,Kimberly Murphy,Helen Nde,Richard Njouom,Diana Nonković,Suzanne Norris,Solomon Obekpa,Stephen Oguche,S. Olafsson,Marian Oltman,Ogu Omede,CE Omuemu,Ohene Opare-Sem,Anne Øvrehus,Shirley Owusu-Ofori,Tsendsuren S. Oyunsuren,George V. Papatheodoridis,Ken Pasini,Kevork M. Peltekian,Richard Phillips,N. N. Pimenov,Hossein Poustchi,Nishi Prabdial-Sing,Huma Qureshi,Alnoor Ramji,Devin Razavi-Shearer,Kathryn Razavi-Shearer,Berhane Redae,Henk W. Reesink,Ezequiel Ridruejo,Sarah Robbins,Lewis R. Roberts,Stuart K. Roberts,William Rosenberg,Françoise Roudot-Thoraval,Stephen D. Ryder,Rifaat Safadi,Olga Sagalova,Riina Salupere,Faisal M. Sanai,Juan F.Sanchez Avila,Vivek A. Saraswat,Rui Sarmento-Castro,Christoph Sarrazin,Jonathan Schmelzer,Ivan Schréter,Carole Seguin-Devaux,Samir Shah,Ala I. Sharara,Manik Sharma,Anatoly Shevaldin,Gamal Shiha,William Sievert,Mark W. Sonderup,Kyriakos Souliotis,Danute Speiciene,Jan Sperl,Peter Stärkel,Rudolf E. Stauber,Catherine A.M. Stedman,Daniel Struck,Tung-Hung Su,Vana Sypsa,Soek Siam Tan,Junko Tanaka,Alexander J. Thompson,Ieva Tolmane,Krzysztof Tomasiewicz,Jonas Valantinas,Pierre Van Damme,Adriaan J. van der Meer,Ingo van Thiel,Hans Van Vlierberghe,Adriana Vince,Wolfgang Vogel,Heiner Wedemeyer,Nina Weis,Vincent Ws Wong,Cesar Yaghi,Ayman Yosry,Man-Fung Yuen,Evy Yunihastuti,Aasim Yusuf,Eli Zuckerman,Homie Razavi +221 more